Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: Safety, efficacy and radiographic outcomes

Rheumatology (United Kingdom)

Volumn 57, Issue 8, 2018, Pages 1423-1431

  Genovese, Mark C ^e   Van Adelsberg, Janet ^a   Fan, Chunpeng ^b   Graham, Neil M H ^a   Van Hoogstraten, Hubert ^b   Parrino, Janie ^a   Mangan, Erin K ^a   Spindler, Alberto ^c   Huizinga, Tom W J ^d   Van Der Heijde, Désirée ^d  

^a Regeneron Pharmaceuticals   (United States)

^b SANOFI   (France)

^c Centro Medico Privado de Reumatologia   (Argentina)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Disease activity; IL 6; Physical function; Radiographic outcomes; Rheumatoid arthritis; Sarilumab

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 6; METHOTREXATE; SARILUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; APPENDIX TUMOR; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CEREBROVASCULAR ACCIDENT; DAS28; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DIVERTICULITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION SITE ERYTHEMA; LEUKOPENIA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC BREAST CANCER; MIDDLE AGED; NEUTROPENIA; OPEN STUDY; OPPORTUNISTIC INFECTION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RADIOGRAPHY; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SMALL INTESTINE CARCINOMA; SQUAMOUS CELL SKIN CARCINOMA; THYROID PAPILLARY CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85049101564     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key121     Document Type: Article

References (19)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094108.
2. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology 2012;51(Suppl 6):vi2836.
3. Smolen JS, Landewe R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:96077.
4. Singh JA, Saag KG, Bridges SL et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:126.
5. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010;2:24756.
6. Genentech, Inc. Actemra [package insert]. South San Francisco, CA, USA, 2016.
7. Rafique A, Martin J, Blome M et al. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6r) alpha. Ann Rheum Dis 2013;72(Suppl 3):A797.
8. Wang L-H, Xue Y, Liu X et al. FRI0020 Preclinical development of sarilumab, the first fully human monoclonal antibody (MAB) against IL-6r alpha: utilization and value of double humanized animal model. Ann Rheum Dis 2013;72(Suppl 3):A375.
9. Zhang L, Luan B, Adler A et al. Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept. Cancer Res 2012;72(8 Suppl):2723.
10. Genovese MC, Fleischmann R, Kivitz AJ et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 2015;67:142437.
11. Emery P, Rondon J, Garg A et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with RA. Arthritis Rheumatol 2015;67(Suppl 10): http://acrabstracts.org/abstract/safety-and-tolerability-of-subcutaneous-sarilumab-compared-to-intravenous-tocilizumab-in-patients-with-ra/.
12. Fleischmann R, van Adelsberg J, Lin Y et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 2017;69:27790.
13. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:98797.
14. Nishimoto N, Miyasaka N, Yamamoto K et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:15804.
15. Kivitz A, Wallace T, Olech E et al. Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b longterm extension study. Rheumatol Ther 2016;3:291304.
16. Moots RJ, Sebba A, Rigby W et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology 2017;56:5419.
17. Weinblatt ME, Keystone EC, Furst DE et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:7539.
18. Wollenhaupt J, Silverfield J, Lee EB et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:83752.
19. Genovese MC, van Hoogstraten H, Kampman W, Jayawardena S, Huizinga TWJ. Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis. Ann Rheum Dis 2017;76(Suppl 2):5767.